Introduction {#section1-1076029619846562}
============

Cardiovascular disease and cancer are the leading causes of death worldwide. Venous thromboembolism (VTE) is the third cause of mortality in cardiovascular disease in Western countries, accounting for 5% to 10% of the deaths of hospitalized patients after ischemic heart disease and stroke.^[@bibr1-1076029619846562]^ The relationship between cancer and VTE has been established. As early as 1823, Jean-Baptiste Bouillaud, a French physician, firstly described the association between cancer and thrombosis.^[@bibr2-1076029619846562]^ It is estimated that about 15% of patients with cancer have symptomatic VTE, while 15% to 20% of patients with VTE are patients with cancer, and approximately 10% of patients with unexplained VTE are diagnosed as tumors within 1 to 2 years.^[@bibr3-1076029619846562]^ The incidence of VTE in the general population is 1/1000 to 2/1000 person-years,^[@bibr4-1076029619846562]^ while the incidence of VTE in patients with cancer has been increasing every year, as high as 13.9/1000 person-years.^[@bibr5-1076029619846562]^ Among first-episode patients with VTE, patients with cancer account for 20% to 30%,^[@bibr6-1076029619846562]^ and only up to 20% of patients with cancer are diagnosed with VTE before death, while up to 50% of patients with cancer are found with VTE at autopsy. This result suggests that the morbidity of VTE may be underestimated.^[@bibr7-1076029619846562]^ Cancer is an independent risk factor for VTE, which occurs between 1% and 11% depending on the type of tumor.^[@bibr8-1076029619846562]^ Meanwhile, VTE is also an independent risk factor for bleeding and death in patients with cancer.^[@bibr7-1076029619846562]^ In fact, VTE is one of the leading causes of death in both outpatient and inpatient patients with cancer.^[@bibr9-1076029619846562]^ After the first episode, the recurrence rate of VTE in patients with anticoagulant therapy is 3.2 times higher than that of noncancer patients (20.7% per year, vs 6.8%), and the incidence of major bleeding is 2.2 times (12.4% per year vs 4.9%).^[@bibr10-1076029619846562]^ In addition, the medical cost of patients with cancer with VTE is approximately 2 times higher than that of non-VTE patients with cancer.^[@bibr11-1076029619846562],[@bibr12-1076029619846562]^

Given the increasing awareness of cancer-associated thrombosis (CAT)-related studies in recent years, it is imperative to evaluate the quality of relevant guidelines to help improve clinical practice for CAT prevention and treatment. However, many issues are yet to be studied and explored despite some existing knowledge of CAT, such as a hypothesis of mechanism and risk factors. One of these issues is the role of new oral anticoagulants (NOACs) in CAT. New oral anticoagulants are also called direct oral anticoagulants in some guidelines. New oral anticoagulant includes direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) and has been established positions in the guidelines for prevention and treatment of atrial fibrillation,^[@bibr13-1076029619846562]^ pulmonary embolism (PE),^[@bibr14-1076029619846562]^ VTE after major orthopedic surgery,^[@bibr15-1076029619846562]^ and so on. In recent years, there have been multiple published guidelines for the prevention and treatment of CAT, so the status of NOAC for CAT needs to be understood and evaluated. In this article, we focus on the quality assessment of the guidelines for CAT with Appraisal of Guidelines for Research & Evaluation II (AGREE II) and the current status of NOAC in CAT.

Methods {#section2-1076029619846562}
=======

A comprehensive literature search (LS) was carried out in PubMed/Medline, Chinese National Knowledge Infrastructure, and other authoritative organization official website using the keywords "cancer-associated thrombosis, guideline, guidance, or consensuses". The specific search strategies, selection criteria, and a flow diagram are shown in Additional File 1 as a supplement. Two review authors independently screened the results. The most recent version of the guideline was included.

Appraisal of Guidelines for Research & Evaluation II,^[@bibr16-1076029619846562]^ a new international tool for quality assessment of guidelines, was utilized to appraise the quality of the selected guidelines. Six domains with 23 items (shown in [Figure 1](#fig1-1076029619846562){ref-type="fig"}) were scored, including: scope and purpose (domain 1), stakeholder involvement (domain 2), rigor of development (domain 3), clarity of presentation (domain 4), applicability (domain 5), and editorial independence (domain 6). Based on the scores of the 6 domains, overall assessment was obtained to assess the quality of the guidelines.

![Six domains and 23 items which are scored by AGREE II. AGREE II indicates Appraisal of Guidelines for Research & Evaluation II.](10.1177_1076029619846562-fig1){#fig1-1076029619846562}

Guideline evaluation was conducted by having 2 independent teams of 3 use AGREE II to score relevant guidelines followed by official training modules. The consistency among the 3 appraisers was tested using intraclass correlation coefficient (ICC): ICC ≥0.75 indicates good agreement, and ICC \<0.4 indicates poor consistency.^[@bibr17-1076029619846562]^ Based on the guidelines, recommendations for anticoagulants and status of NOAC for VTE prevention and treatment in the different groups of patient with CAT were summarized.

Results {#section3-1076029619846562}
=======

Quality Evaluation of the Guidelines {#section4-1076029619846562}
------------------------------------

A total of 19 related guidelines were retrieved, ranked by years of publication as listed in [Table 1](#table1-1076029619846562){ref-type="table"}. Most languages were in English (17/19), except 1 in Chinese and 1 in Spanish.

###### 

List of the 19 Guidelines for CAT.

![](10.1177_1076029619846562-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Organizations/Authors                                                                                                                                                                                      Names                                                                                                                                                                                                                                                                                                                                                                Years   Languages   Recommendations   Alternative agents (NOAC)                                 
  ----- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ----------- ----------------- --------------------------- ---- ---- ---- ---- ---- ---- ----
  G1    European Society for Medical Oncology (ESMO)                                                                                                                                                               Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines^[@bibr18-1076029619846562]^                                                                                                                                                                                                                                         2011    English     SR                SR                          SR   SR   SR                  

  G2    Italian Society for Haemostasis and Thrombosis (SISET)                                                                                                                                                     Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)^[@bibr19-1076029619846562]^                                                                                                                                                                                                   2012    English     SR                SR                          SR   SR   LS                  

  G3    Debourdeau et al                                                                                                                                                                                           International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer^[@bibr20-1076029619846562]^                                                                                                                                                                              2013    English     SR                SR                          SR                            

  G4    American Society of Clinical Oncology (ASCO)                                                                                                                                                               Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014^[@bibr21-1076029619846562]^                                                                                                                                                                                  2014    English     LS                                                      LS                  

  G5    Scientific and Standardization Committee (SSC) of International Society on Thrombosis and Haemostasis (ISTH)                                                                                               Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH^[@bibr22-1076029619846562]^                                                                                                                                                                                                                    2014    English     SR                SR                          SR                            

  G6    Scientific and Standardization Committee (SSC) of International Society on Thrombosis and Haemostasis\                                                                                                     Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH^[@bibr23-1076029619846562]^                                                                                                                                                                                                                                            2014    English     SR                                                      SR                  
        (ISTH) \[SSC/ISTH\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  G7    Scientific and Standardization Committee (SSC) of International Society on Thrombosis and Haemostasis (ISTH)\[SSC/ISTH\]                                                                                   Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH^[@bibr24-1076029619846562]^                                                                                                                                                                                                                          2014    English     LS                                            LS   LS                       

  G8    Spanish Society of Medical Oncology (SEOM)                                                                                                                                                                 Clinical guide SEOM on venous thromboembolism in cancer patients^[@bibr25-1076029619846562]^                                                                                                                                                                                                                                                                         2014    English     SR                LS                          SR        SR                  

  G9    Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO), and Society of Thrombosis and Haemostasis Research (GTH e.V.)   Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)^[@bibr26-1076029619846562]^   2014    English     LS                LS                          LS   LS        LS   LS   LS   

  G10   British Committee for Standards in Haematology (BCSH)                                                                                                                                                      Guideline on aspects of cancer-related venous thrombosis^[@bibr27-1076029619846562]^                                                                                                                                                                                                                                                                                 2015    English     SR                LS                          LS             LS   LS   LS   LS

  G11   Spanish Society of Angiology and Vascular Surgery (SEACV)/Spanish Society of Medical Oncology (SEOM)                                                                                                       Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM^[@bibr28-1076029619846562]^                                                                                                                                                                                                          2015    Spanish     SR                SR                          SR   SR   SR                  

  G12   Saudi Association for Venous Thrombo Embolism and Saudi Scientific Hematology Society                                                                                                                      Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline^[@bibr29-1076029619846562]^                                                                                                                                                                                                                       2015    English     SR                SR                          SR                            

  G13   Expert consensus Committee on Oncology and Thrombosis of Chinese Society of Clinical Oncology (CSCO)                                                                                                       Prevention and treatment of tumor-related venous thromboembolism Chinese Expert Guide (2015 Edition)^[@bibr30-1076029619846562]^                                                                                                                                                                                                                                     2015    Chinese     LS                LS                          LS   LS                       

  G14   Easaw et al                                                                                                                                                                                                Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Prophylaxis and treatment^[@bibr31-1076029619846562]^                                                                                                                                                                                                        2015    English     SR                SR                                                        

  G15   Carrier et al                                                                                                                                                                                              Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations^[@bibr32-1076029619846562]^                                                                                                                                                                                                                             2015    English     SR                SR                                                        

  G16   International Initiative on Thrombosis and Cancer (ITAC-CME)                                                                                                                                               International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer^[@bibr33-1076029619846562]^                                                                                                                                                          2016    English     SR                SR                          SR   SR        LS   LS   LS   LS

  G17   Khorana et al                                                                                                                                                                                              Guidance for the prevention and treatment of cancer-associated venous thromboembolism^[@bibr34-1076029619846562]^                                                                                                                                                                                                                                                    2016    English     SR                SR                          LS   LS   LS                  

  G18   Wojtukiewicz et al, Polish Society of Clinical Oncology and Working Group on Haemostasis of the Polish Society of Haematology and Transfusion Medicine                                                     Guidelines for the prevention and treatment of venous thromboembolism in non-surgically treated cancer patients^[@bibr35-1076029619846562]^                                                                                                                                                                                                                          2016    English     SR                SR                          SR   SR   SR   SR   SR   SR   

  G19   National Comprehensive Cancer Network (NCCN)                                                                                                                                                               NCCN Guidelines Version 1. 2017 Updates Cancer Associated Venous Thromboembolic Disease^[@bibr36-1076029619846562]^                                                                                                                                                                                                                                                  2017    English     SR                SR                          SR   SR   SR   SR   SR   SR   SR
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Asp, asprin; CAT, cancer-associated thrombosis; Fx, fondaparinux; ISTH, International Society on Thrombosis and Haemostasis; LMWH, low molecular weight heparin; LS, literature search; NOAC, new oral anticoagulant; SEOM, Spanish Society of Medical Oncology; SR, systemic review; SSC; Scientific and Standardization Committee; UFH, unfractionated heparin; VKA, vitamin K antagonist.

Six domains of the 19 guidelines were evaluated using the AGREE II tool, with scores were listed in [Table 2](#table2-1076029619846562){ref-type="table"}. High-quality guidelines were categorized to have a threshold score of over 70%.^[@bibr16-1076029619846562]^ The scores of overall assessment for the 19 guidelines were among 3 to 6 point (the maximum score was 7 points). Among them, 8 guidelines (5 or 6 points) were recommended, 5 guidelines (4 points) were recommended after revised, while 6 guidelines (3 points) were not recommended.

###### 

Domain Scores and Recommendations for the 19 Guidelines Using AGREE II Tool.

![](10.1177_1076029619846562-table2)

                                      G1      G2      G3      G4      G5      G6      G7      G8      G9      G10     G11     G12     G13     G14     G15     G16     G17     G18     G19
  ----------------------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Domain 1: Scope and purpose         57%     78%     56%     65%     52%     61%     46%     54%     80%     80%     83%     76%     83%     90%     70%     87%     72%     81%     87%
  Domain 2: Stakeholder involvement   41%     41%     65%     57%     20%     28%     37%     30%     37%     35%     37%     37%     50%     52%     44%     87%     15%     52%     91%
  Domain 3: Rigour of development     60%     73%     78%     40%     38%     38%     39%     47%     33%     84%     71%     64%     42%     79%     67%     85%     50%     54%     88%
  Domain 4: Clarity of presentation   87%     83%     85%     83%     81%     81%     81%     89%     89%     93%     87%     85%     91%     94%     89%     89%     70%     87%     91%
  Domain 5: Applicability             53%     31%     57%     39%     36%     39%     22%     30%     50%     63%     63%     54%     67%     75%     46%     67%     57%     42%     72%
  Domain 6: Editorial independence    47%     56%     94%     97%     86%     97%     50%     97%     53%     53%     56%     8%      28%     53%     81%     53%     69%     6%      100%
  Overall Assessment (max score 7)    4       5       6       4       3       4       3       4       3       5       5       3       4       6       5       6       3       3       6
  ICC                                 0.913   0.896   0.839   0.899   0.865   0.922   0.893   0.937   0.878   0.851   0.820   0.811   0.913   0.912   0.855   0.874   0.824   0.852   0.821
  Recommendation                      Y-M     Y       Y       Y-M     N       Y-M     N       Y-M     N       Y       Y       N       Y-M     Y       Y       Y       N       N       Y

Abbreviations: AGREE II, Appraisal of Guidelines for Research & Evaluation II; ICC, intraclass correlation coefficient; N, no; Y, yes; Y-M, yes, with modification.

The scores of 6 domains for the 19 guidelines are shown in [Figure 2](#fig2-1076029619846562){ref-type="fig"}, with each domain's score distribution and variance. Domain 2 (stakeholder involvement) and domain 5 (applicability) were of lower quality with the scores of 45% (19%; mean \[standard deviation, SD\]) and 52% (16%), respectively. The coefficient of variation (CV) of each domain in descending order was domain 6 (45.70%) \> domain 2 (42.37%) \> domain 5 (30.91%) \> domain 3 (30.72%) \> domain 1 (19.16%) \> domain 4 (6.50%).

![Score distribution of the 6 domains among the 19 guidelines.](10.1177_1076029619846562-fig2){#fig2-1076029619846562}

Intraclass correlation coefficient was used to measure the consistency when performing a quality appraisal of the guidelines among the 3 appraisers, and our results are shown in [Table 2](#table2-1076029619846562){ref-type="table"}. All the ICC are \>0.75, indicating that the agreement was consistent with each other.

Venous Thromboembolism Prevention and Treatment in Patients With Cancer and Status of NOAC in CAT {#section5-1076029619846562}
-------------------------------------------------------------------------------------------------

Below is a summary of anticoagulant suggestions for VTE prevention and treatment in different types of patients with cancer followed by the 19 guidelines (shown in [Table 3](#table3-1076029619846562){ref-type="table"}).

###### 

Anticoagulant Recommendations for VTE Prevention and Treatment in Patients With Cancer.

![](10.1177_1076029619846562-table3)

  No.   Recommendations                                                                                                                                                                                                                                                                          
  ----- ------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------
  G1    LMWH (2B), Asp (2B), warfarin (2B)                      LMWH (1A), UFH (1A), Fx (1A)                       LMWH (1A), UFH (1A)                                                                                     LMWH, UFH                                                             LMWH (1A)
  G2    LMWH (C), Asp (C), Warfarin (C)                         LMWH (A), UFH (A), Fx (A)                          LMWH (A), UFH (A), Fx (A)                                                                                                                                                     
  G3                                                                                                                                                                                                                                                                                             LMWH, VKA
  G4    LMWH, Asp                                                                                                                                                                                                          LMWH                                                                  
  G5                                                                                                                                                                                                                                                                                             LMWH
  G6    LMWH, Asp                                                                                                                                                                                                                                                                                
  G7                                                            LMWH, UFH                                                                                                                                                                                                                        
  G8    LMWH (2B), Asp (2B)                                     LMWH (1B)                                          LMWH                                                                                                    LMWH (1A)                                                             LMWH (1A)
  G9                                                                                                               LMWH                                                                                                    LMWH, Fx, NOACs (apixaban, rivaroxaban), (UFH)                        LMWH, VKA, NOACs (apixaban, dabigatran, rivaroxaban)
  G10                                                                                                                                                                                                                      LMWH, warfarin, NOACs (apixaban, dabigatran, rivaroxaban, edoxaban)   LMWH (1A), warfarin, oral anticoagulants
  G11   LMWH (2B), Asp (2B)                                     LMWH (1B)                                          LMWH (1A), UFH (1A)                                                                                     LMWH (1A)                                                             LMWH (1A), VKA (1A)
  G12   UFH, oral anticoagulation, parenteral anticoagulation                                                                                                                                                              LMWH                                                                  LMWH, VKA
  G13                                                           LMWH, UFH, Fx                                                                                                                                              LMWH, UFH, Fx                                                         LMWH, warfarin
  G14                                                           LMWH (1B)                                                                                                                                                                                                                        LMWH
  G15                                                                                                                                                                                                                      LMWH                                                                  LMWH, warfarin
  G16                                                           LMWH (1B), UFH (1B), Fx (1B), VKA (2C), Asp (2C)   LMWH (1A), UFH                                                                                          LMWH (1B), Fx (2D), UFH (2D)                                          LMWH (1A), NOACs (apixaban, dabigatran, rivaroxaban, edoxaban)
  G17   LMWH, Asp                                               LMWH, UFH, Fx                                      LMWH, UFH, Fx                                                                                           LMWH, UFH, Fx                                                         LMWH, warfarin
  G18   LMWH (1B), VKA (1B), Asp (1B)                           LMWH (1A), UFH (1A), Fx (1A)                                                                                                                               LMWH (1B), UFH (2C), Fx (2C)                                          LMWH, VKA(1B), NOACs (apixaban, dabigatran, rivaroxaban), (2C)
  G19   LMWH (2A), Asp (2A), warfarin (2A)                      LMWH (2A), Fx (2A), UFH (2A), warfarin (2A)        LMWH (2A), UFH (2A), warfarin (2A), Fx (2A), NOACs (apixaban, dabigatran, rivaroxaban, edoxaban) (2A)   LMWH (2A), UFH (2A), Fx (2A), NOACs (apixaban, rivaroxaban) (2A)      LMWH (1A), warfarin (2A), NOACs (apixaban, dabigatran, rivaroxaban, edoxaban) (2A)

Abbreviations: Asp, asprin; Fx, fondaparinux; LMWH, low-molecular-weight heparin; NOACs, new oral anticoagulants; PE, pulmonary embolism; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism.

### Venous thromboembolism prevention in cancer outpatients {#section6-1076029619846562}

Most cancer outpatients do not require routine prevention (2B).^[@bibr21-1076029619846562],[@bibr23-1076029619846562],[@bibr27-1076029619846562],[@bibr28-1076029619846562]^ It may be suitable for preventing for the following types of particularly high-risk VTE conditions: multiple myeloma with thalidomide or lenalidomide regimens,^[@bibr23-1076029619846562],[@bibr27-1076029619846562],[@bibr28-1076029619846562]^ high Khorana scores,^[@bibr23-1076029619846562],[@bibr37-1076029619846562]^ some with a prior history of VTE.^[@bibr23-1076029619846562]^

The duration of the prophylaxis and the indications for discontinuation were unknown; low-molecular-weight heparin (LMWH) was recommended (2B).^[@bibr25-1076029619846562]^ New oral anticoagulant was not compared with LMWH in an outpatient setting.

### Venous thromboembolism prevention in hospitalized (illness) patients with cancer {#section7-1076029619846562}

Venous thromboembolism prevention is recommended when there is no contraindication in hospitalized patients with limited activity (1B).^[@bibr31-1076029619846562]^ Patients without limited activity, if not contraindicated, may also benefit from prevention (2B).^[@bibr31-1076029619846562]^ Patients who receive systemic chemotherapy do not need routine prevention.^[@bibr33-1076029619846562]^ However, for locally advanced or metastatic pancreatic cancer and locally advanced or metastatic lung cancer, thalidomide and renatamide (prophylaxis with LMWH, vitamin K antagonist \[VKA\], or aspirin) are recommended (2C).^[@bibr33-1076029619846562]^ Routine prophylaxis is not recommended for patients admitted to hospital with short-term chemotherapy infusion or small procedure.^[@bibr24-1076029619846562],[@bibr35-1076029619846562]^ Low-molecular-weight heparin is recommended (1B), although it is unclear which one is superior among LMWH, fondaparinux, and unfractionated heparin (UFH) from current studies.^[@bibr31-1076029619846562]^ New oral anticoagulant was not compared with LMWH in this setting, either.

### Venous thromboembolism prevention in hospitalized (surgical) patients with cancer {#section8-1076029619846562}

Prevention is recommended in most surgical patients with cancer, but not required for those with smaller operations.^[@bibr34-1076029619846562]^ The prophylaxis was 12 to 2 hours before operation or 6 to 12 hours after the operation, usually lasting for 7 to 10 days (1A).^[@bibr28-1076029619846562],[@bibr33-1076029619846562]^ The duration of prevention of extensive abdominal and pelvic surgery is 4 weeks (1B).^[@bibr19-1076029619846562],[@bibr28-1076029619846562],[@bibr31-1076029619846562]^ The use of LMWH, fondaparinux, and UFH depends on the patient's characteristics. There are no NOAC trials for this type of patients.

### Venous thromboembolism (PE) treatment in patients with cancer {#section9-1076029619846562}

#### Initial treatment (5 to 10 days) {#section10-1076029619846562}

Low-molecular-weight heparin is preferred (1A).^[@bibr25-1076029619846562],[@bibr28-1076029619846562],[@bibr29-1076029619846562]^ Unfractionated heparin or fondaparinux can also be used (2D).^[@bibr33-1076029619846562]^ If LMWH cannot be used, NOAC can be considered.^[@bibr26-1076029619846562],[@bibr27-1076029619846562],[@bibr36-1076029619846562]^

#### Long-term treatment (3 to 6 months) {#section11-1076029619846562}

Low-molecular-weight heparin is preferred over VKA (1A).^[@bibr18-1076029619846562],[@bibr33-1076029619846562]^ If LMWH is not applicable, NOAC is an acceptable alternative, which lasts for at least 3 months.^[@bibr36-1076029619846562]^ Although 6 months is recommended from 2 large trials, the evidence level is low. Compared with VKA, the survival rate of patients with cancer using LMWH remains the same. However, recurrence-risk decreases during the treatment of VTE, and the risk of massive hemorrhage does not increase.^[@bibr25-1076029619846562],[@bibr29-1076029619846562]^ In contrast with VKA, the risk of recurrence of VTE in patients with cancer used NOAC is lower, whereas that of massive hemorrhage does not increase.^[@bibr33-1076029619846562]^ There is no data to show that LMWH is directly compared with NOAC in the safety and effectiveness when the guidelines are issued. Some trials are underway and may yield results in the near future.

#### Extended-term therapy (\> 3 to 6 months) {#section12-1076029619846562}

Venous thromboembolism (PE) treatment depends on whether the tumor is active, progressive, metastatic, under treatment, or cure.^[@bibr33-1076029619846562]^ The risk of recurrence and bleeding in VTE should be weighted. Tumor types, costs, survival expectations, treatment options, and patient willingness might be considered. The research in this filed is paucity. The recurrence risk assessment scale (Ottawa Score)^[@bibr38-1076029619846562],[@bibr39-1076029619846562]^ has to be verified.

Discussions {#section13-1076029619846562}
===========

A total of 19 guidelines for the prevention and treatment of CAT were screened out and evaluated. Appraisal of Guidelines for Research & Evaluation II tool was used to evaluate the quality of the guidelines, and the higher score indicates better quality. The evaluation showed inconsistent quality results among the 19 guidelines, with scores of 3 to 6 points (the maximum score was 7 points). This result indicates that the quality of these guidelines needs to be further improved. Among the 6 domains, domain 2 (stakeholder involvement) and domain 5 (applicability) were of lower quality with the scores of 45% (19%) and 52% (16%), respectively. This suggests that the extent of developers, intended users, and their views was not described or considered sufficiently in the process of the guideline development. Meanwhile, facilitators and barriers, tools, and resources for application were also presented or provided insufficiently. Domain 4 (clarity of presentation) with the scores of 86% (6%) and the CV of 6.50% indicates that clarity of presentation of all guidelines is the most assuring, while domain 2 (stakeholder involvement) is the least guaranteed.

In summary, different anticoagulants are recommended in cancer outpatients, hospitalized (illness) patients with cancer, and hospitalized (surgical) patients with cancer. As shown in [Table 1](#table1-1076029619846562){ref-type="table"}, LMWH is recommended in all the 19 guidelines, 15 of which were based on systematic reviews (SRs) and the other 4 on LSs. Vitamin K antagonist is recommended in 16 guidelines, 12 of which were based on SRs and the other 4 on LSs. The other 3 anticoagulants of UFH, fondaparinux, and aspirin are also recommended, but their recommendation levels are lower than LMWH and VKA. As to NOAC, only 5 guidelines recommend them, and the evidence sources are LSs. Therefore, LMWH and VKA are still the most recommended anticoagulants for prevention and treatment of CAT overall.

The development of guidelines is generally based on evidence-based medicine. Relative CAT trials with anticoagulants are summarized and listed in [Table 4](#table4-1076029619846562){ref-type="table"}. CLOT trial (2003) and Long-term Innovations in TreatmEnt program (LITE) trial (2006) earn a place of LMWH over in the treatment of VTE in patients with cancer. The subgroup analysis of randomized controlled trial has proved that NOAC is superior to warfarin. Although the evidence on the direct comparison of NOAC with LMWH is lacking, the results of Hokusai-VTE (2017.12) and the first phase of SELECT-D trial suggest that NOAC is not less effective than LMWH. The incidence of major bleeding in the NOAC group was higher than that of LMWHs group, but there was no significant differences between the 2 groups. SELCET-D trial displays significantly higher clinically relevant nonmajor bleeding in NOAC group (6/203, 3% vs 25/203, 12%). The patient's own bleeding risk factors should also be considered in the selection of NOAC. Future trials will provide more evidence to elucidate the role of NOAC in the treatment of CAT. In addition, because of the particularity of the patients enrolled in the studies, the significance of the POOL study remains to be discussed. Studies on extended-term treatment of VTE, especially longer than 6 months and the regimen of VTE recurrence are scanty. There is a shortage in study on NOAC in cancer-related thromboprophylaxis and catheter-associated thrombosis in patients with cancer. These areas above are some directions for future research.

###### 

Trials of Anticoagulants in CAT.

![](10.1177_1076029619846562-table4)

  Category                                                      Original Trials (Published/Anticipated Time)             Anticoagulants   Duration, in Months   VTE Recurrence   Major Bleeding            
  ------------------------------------------------------------- -------------------------------------------------------- ---------------- --------------------- ---------------- ---------------- -------- -----
  Randomized controlled trials (RCTs) had long been completed   CATHENOX (2002)                                          Warfarin         3                     3/75             6.7              12/75    16
                                                                Enoxaparin                                                                2/71                  2.8              5/71             7.0      
  CLOT (2003)                                                   Warfarin                                                 6                53/336                15.8             12/335           3.6      
                                                                Dalteparin                                                                27/336                8.0              19/338           5.6      
                                                                                                                                                                                                           
  ONCENOX (2006)                                                Enoxaparin to warfarin                                   6                3/30                  10               1/34             2.9      
                                                                Enoxaparin                                                                2/29                  6.9              2/31             6.5      
                                                                Enoxaparin (different dosage)                                             2/32                  6.3              4/36             11.1     
  LITE (2006)                                                   IV heparin or warfarin                                   3                16/100                16               7/100            7        
                                                                Tinzaparin                                                                7/100                 7                7/100            7        
  CATCH (2015)                                                  warfarin                                                 6                45/451                10.5             11/451           2.4      
                                                                Tinzaparin                                                                31/449                7.2              12/449           2.1      
  Analysis of subgroups had long been completed                 AMPLIFY (2003)                                           warfarin         6                     5/78             6.4              4/80     5.0
                                                                Apixaban                                                                  3/81                  3.7              2/87             2.3      
  EINSTEIN (PE + DVT) (2013)                                    warfarin                                                 3-12             8/204                 3.9              8/204            3.9      
                                                                Rivaroxaban                                                               6/258                 2.3              5/238            2.1      
  RE-COVER (I, II) (2013)                                       Warfarin                                                 6                3/57                  5.3              3/57             5.3      
                                                                Dabigatran                                                                2/64                  3.1              6/159            7.8      
  Hokusai-VTE (2015)                                            Warfarin                                                 3-12             7/99                  7.1              3/99             3        
                                                                Edoxaban                                                                  4/109                 3.7              5/109            4.6      
  RCT was just completed                                        Hokusai-VTE (2017.12)                                    Edoxaban         6-12                  41/522           7.9              36/522   6.9
                                                                Dalteparin                                                                59/524                11.3             21/524           4.0      
  RCTs are on going                                             CASTA-DIVA (2018.5)                                      Rivaroxaban      3                                                                
                                                                Dalteparin                                                                                                                                 
  SELET-D^a^ (2018.12)                                          Rivaroxaban                                              6+6              8/202                 4                6/202            3        
                                                                Dalteparin                                                                18/202                11               11/202           5        
  CONKO 011 (2018.3)                                            Rivaroxaban                                              3                                                                                 
                                                                LMWH (enoxa-/tinza-/dalteparin)                                                                                                            
  CANVAS (2019.12)                                              NOAC (Rivaro-/Api-/edoxaban; dabigatran)                 6                                                                                 
                                                                LMWH (enoxaparin/dalteparin/fondaparinux) and warfarin                                                                                     

Abbreviations: CAT, cancer-associated thrombosis; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; NOACs, new oral anticoagulants; PE, pulmonary embolism; RCTs, randomized controlled trials; VTE, venous thromboembolism.

^a^Main results of first phase of the study.

Conclusion {#section14-1076029619846562}
==========

Based on the assessment by AGREE II, the qualities of the 19 CAT guidelines were varied, 8 of which (guideline 2, 3, 10, 11, 14, 15, 16, 19) were recommended, while others recommended after revised, or not recommended. Special attention should be paid to domain 2 and 5 (lower scores) and domain 6 (largest variations) when developing or revising CAT guidelines. For prevention and treatment of CAT, LMWH is the most recommended, followed by VKA, UFH, fondaparinux, and aspirin. The role of NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) in the treatment of CAT is gradually established, but more supporting evidence is needed from the current and future clinical trials.
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